Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.40
    -0.14 (-1.86%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Maravai Lifesciences Holdings Inc (MRVI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Maravai Lifesciences Holdings reported revenue of $185.74M for the fiscal year ended Dec 31, 2025, down 28.3% from the year before. That year, net income was -$230.76M with a net margin of -124.2%, operating cash flow was -$57.57M and free cash flow was -$70.72M. The quarter ended Sep 30, 2026 had revenue of $45.85M and net income of -$24.00M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue grew from $123.83M, a compound annual rate of 6.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$185.74M-28.3%18.3%-115.9%-124.2%
    Dec 2024$259.19M-10.3%41.8%-90.9%-100.2%
    Dec 2023$288.94M-67.3%48.5%-11.0%-47.9%
    Dec 2022$883.00M+10.5%80.9%65.0%55.6%
    Dec 2021$799.24M+181.3%82.4%69.4%58.7%
    Dec 2020$284.10M+98.5%72.0%42.2%27.7%
    Dec 2019$143.14M+15.6%53.3%16.8%-3.6%
    Dec 2018$123.83MN/A50.9%13.3%-14.3%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$185.74M$259.19M$288.94M$883.00M$799.24M$284.10M$143.14M$123.83M
    Cost of revenue$151.75M$150.88M$148.74M$168.96M$140.56M$79.65M$66.85M$60.77M
    Gross profit$33.99M$108.31M$140.20M$714.04M$658.68M$204.45M$76.29M$63.07M
    Research and development$17.40M$19.22M$17.28M$18.37M$15.22M$9.30M$3.63M$4.50M
    Operating income-$215.27M-$235.62M-$31.65M$574.22M$554.64M$119.90M$23.99M$16.44M
    Net income-$230.76M-$259.62M-$138.38M$490.66M$469.25M$78.82M-$5.20M-$17.73M
    EBITDA-$157.29M-$178.24M$687.61M$614.75M$597.25M$147.69M$49.92M$33.25M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$45.85M$51.44M$65.84M$49.87M$41.63M$47.40M$46.85M$56.56M$69.03M$69.42M$64.18M$74.14M
    Gross profit$16.19M$20.65M$33.70M$12.84M$5.66M$7.77M$7.72M$19.39M$32.23M$30.84M$25.84M$39.03M
    Operating income-$20.62M-$15.09M-$2.16M-$58.80M-$41.03M-$66.28M-$49.16M-$37.70M-$165.61M-$13.44M-$18.86M-$7.15M
    Net income-$24.00M-$21.63M-$6.38M-$63.02M-$45.06M-$69.84M-$52.85M-$46.07M-$172.46M-$18.42M-$22.68M-$109.98M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $291.77M exceeded cash and equivalents by $74.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$770.58M$1.01B$1.49B$2.28B$1.92B$1.27B$577.80M$539.68M
    Current assets$296.25M$429.15M$699.91M$847.90M$740.04M$331.60M$60.55M$53.80M
    Cash and equivalents$216.89M$322.40M$574.96M$632.14M$551.27M$236.18M$24.70M$21.87M
    Total liabilities$397.87M$431.04M$697.57M$1.38B$1.37B$1.12B$433.17M$391.66M
    Short-term debt$5.44M$5.44M$5.44M$5.44M$6.00M$6.00M$2.50M$2.50M
    Long-term debt$286.33M$290.49M$518.71M$522.00M$524.59M$528.61M$334.78M$335.55M
    Shareholder equity$212.38M$325.29M$416.75M$545.22M$315.50M$88.51M$141.40M$144.41M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$600.07M$603.75M$713.22M$770.58M$849.19M$896.97M$959.75M$1.01B$1.28B$1.45B$1.44B$1.49B
    Total liabilities$259.90M$248.16M$344.13M$397.87M$417.33M$428.98M$429.48M$431.04M$665.09M$671.19M$667.25M$697.57M
    Cash and equivalents$73.02M$70.09M$165.92M$216.89M$243.57M$269.91M$285.05M$322.40M$578.16M$573.17M$561.69M$574.96M
    Shareholder equity$195.89M$204.62M$211.56M$212.38M$245.44M$265.86M$300.61M$325.29M$345.14M$436.93M$410.66M$416.75M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$57.57M$7.46M$126.22M$535.98M$368.57M$152.19M$24.11M-$186.00K
    Capital expenditures$13.15M$29.66M$65.55M$17.09M$14.85M$25.41M$17.15M$3.61M
    Free cash flow-$70.72M-$22.19M$60.67M$518.89M$353.72M$126.78M$6.97M-$3.80M
    Dividends paidN/AN/AN/A$150.21M$153.45M$425.11M$0$52.06M
    Share repurchasesN/AN/AN/AN/AN/A$42.80M$227.00KN/A
    Investing cash flow-$31.41M-$24.32M-$122.31M-$267.61M$105.66M$6.07M-$17.15M-$3.45M
    Financing cash flow-$16.50M-$235.71M-$61.09M-$187.50M-$159.05M$53.21M-$4.17M-$9.17M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$5.01M$3.99M$8.66M-$22.77M-$15.15M-$10.27M-$9.39M-$14.64M$13.14M$17.43M-$8.47M$7.79M
    Capital expenditures$523.00K$370.00K$4.44M$2.11M$2.93M$2.87M$4.50M$5.85M$8.59M$9.55M$5.67M$16.80M
    Free cash flow$4.49M$3.62M$4.23M-$24.88M-$18.08M-$13.14M-$13.89M-$20.49M$4.54M$7.88M-$14.13M-$9.01M
    Last 12 quarters

    Frequently Asked Questions About MRVI

    What is Maravai Lifesciences Holdings' annual revenue?

    Maravai Lifesciences Holdings reported revenue of $185.74M for the fiscal year ended Dec 31, 2025.

    How fast is Maravai Lifesciences Holdings' revenue growing?

    Revenue was down 28.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -40.5%.

    Is Maravai Lifesciences Holdings profitable?

    No. Maravai Lifesciences Holdings reported net income of -$230.76M for the fiscal year ended Dec 31, 2025, with a net margin of -124.2%.

    How much free cash flow does MRVI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$57.57M minus capital expenditures of $13.15M produced free cash flow of -$70.72M.

    How much debt does Maravai Lifesciences Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $286.33M, short-term debt of $5.44M and cash and equivalents of $216.89M.